Brigatinib

Chemical formula: C₂₆H₃₄ClN₆O₂P  Molecular mass: 584.1 g/mol  PubChem compound: 68165256

Therapeutic indications

Brigatinib is indicated for:

Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Population group: only adults (18 years old or older)

Brigatinib is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

Brigatinib is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2020: ALUNBRIG Film-coated tablet
Summary of Product Characteristics (SPC) 2021: ALUNBRIG Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈